3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione
Structure Info
- Chemspace ID
- CSSB03437854222 (In-Stock Building Blocks)
- CAS
- 2698398-71-7
- MFCD
- MFCD33549746
- IUPAC Name
- 3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione
- Mol formula
- C19H23BN2O5
- Mol weight
- 370 Da
- Catalog Number(s)
- 199638, AA027KUY, AG027KXQ, AKOS040988395, ArZ-UP229369, BB4LS-EN300-7351981, BBLS03437854222, BD02308744, BL12758, EN300-7351981, F92216, HTS058231, HY-W998267, PBMR1465076, ST027MEI, TX027M3E, Y225133, Y3133788, Z3660952592, ZX-NM249375, ZXC241840, bbls03437854222
- Copy structure to query editor
- SMILES
- INCHI
- INCHI key
- MOL
Properties
- LogP
- 1.79
- Heavy atoms count
- 27
- Rotatable bond count
- 2
- Number of rings
- 4
- Carbon bond saturation, Fsp3
- 0.526
- Polar surface area (Å)
- 85
- Hydrogen bond acceptors count
- 5
- Hydrogen bond donors count
- 1
- Zoom the structure
- CSSB03437854222
Items Overall 57 items from 12 suppliers
| Supplier | Lead time | Ships from | Purity | Pack | Price, $ | Qty |
|---|---|---|---|---|---|---|
| BB4LS US | 2 days | United States To: | 95 | 50 umol | 141.44 | |
| BB4LS US | 2 days | United States To: | 95 | 100 umol | 193.56 | |
| BB4LS US | 2 days | United States To: | 95 | 200 umol | 279.00 | |
| BB4LS US | 2 days | United States To: | 95 | 300 umol | 336.00 | |
| BB4LS US | 2 days | United States To: | 95 | 500 umol | 414.00 | |
| Advanced ChemBlocks CN | 3 days | China To: | 95 | 250 mg | 775.00 | |
| Advanced ChemBlocks CN | 3 days | China To: | 95 | 1 g | 1,515.00 | |
| Advanced ChemBlocks CN | 3 days | China To: | 95 | 5 g | 3,875.00 | |
Description: 3-(1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-2-yl)piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 50 mg | 216.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 100 mg | 322.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 250 mg | 459.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 500 mg | 723.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 1 g | 928.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 2.5 g | 1,819.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 5 g | 2,691.00 | |
| Enamine Ltd. | 5 days | Ukraine To: | 95 | 10 g | 3,992.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 50 mg | 216.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 100 mg | 322.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 250 mg | 459.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 500 mg | 723.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 1 g | 928.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 2.5 g | 1,819.00 | |
| Enamine LV SIA | 5 days | Latvia To: | 95 | 5 g | 2,691.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 50 mg | 216.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 100 mg | 322.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 250 mg | 459.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 500 mg | 723.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 1 g | 928.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 2.5 g | 1,819.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 5 g | 2,691.00 | |
| Enamine US, Inc. | 5 days | United States To: | 95 | 10 g | 3,992.00 | |
| BB4LS EU | 7 days | Germany To: | 95 | 50 umol | 141.44 | |
| BB4LS EU | 7 days | Germany To: | 95 | 100 umol | 193.56 | |
| BB4LS EU | 7 days | Germany To: | 95 | 200 umol | 279.00 | |
| BB4LS EU | 7 days | Germany To: | 95 | 300 umol | 336.00 | |
| BB4LS EU | 7 days | Germany To: | 95 | 500 umol | 414.00 | |
| Angene International Limited | 10 days | China To: | 95 | 50 mg | 363.60 | |
| Angene International Limited | 10 days | China To: | 95 | 100 mg | 540.00 | |
| Angene International Limited | 10 days | China To: | 95 | 250 mg | 765.00 | |
Description: 3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
| Advanced ChemBlock Inc | 10 days | United States To: | 95 | 250 mg | 775.00 | |
| Advanced ChemBlock Inc | 10 days | United States To: | 95 | 1 g | 1,515.00 | |
| Advanced ChemBlock Inc | 10 days | United States To: | 95 | 5 g | 3,875.00 | |
Description: 3-(1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindolin-2-yl)piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
| Astatech CN | 10 days | China To: | 95 | 100 mg | 822.80 | |
| Astatech CN | 10 days | China To: | 95 | 250 mg | 1,644.50 | |
| Astatech CN | 10 days | China To: | 95 | 1 g | 3,289.00 | |
Description: 3-[1-OXO-6-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)-2,3-DIHYDRO-1H-ISOINDOL-2-YL]PIPERIDINE-2,6-DIONE; CAS: 2698398-71-7 | ||||||
| AA BLOCKS | 12 days | United States To: | 90 | 100 mg | 492.80 | |
| AA BLOCKS | 12 days | United States To: | 90 | 250 mg | 783.20 | |
| AA BLOCKS | 12 days | United States To: | 90 | 500 mg | 1,054.90 | |
| AA BLOCKS | 12 days | United States To: | 90 | 1 g | 1,435.50 | |
Description: 3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
| A2B Chem | 12 days | United States To: | 95 | 100 mg | 508.30 | |
| A2B Chem | 12 days | United States To: | 95 | 250 mg | 813.05 | |
| A2B Chem | 12 days | United States To: | 95 | 500 mg | 1,097.10 | |
| A2B Chem | 12 days | United States To: | 95 | 1 g | 1,493.85 | |
Description: 3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
| 1st Scientific LLC | 14 days | United States To: | 95 | 100 mg | 459.80 | |
| 1st Scientific LLC | 14 days | United States To: | 95 | 250 mg | 721.60 | |
| 1st Scientific LLC | 14 days | United States To: | 95 | 500 mg | 965.80 | |
| 1st Scientific LLC | 14 days | United States To: | 95 | 1 g | 1,307.90 | |
Description: 3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione; CAS: 2698398-71-7 | ||||||
For a custom pack size or bulk
please drop us a line:Enquire
please drop us a line:Enquire
![Chemical structure of (3S)-3-[1-oxo-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione - CSSB21511091595](/st/structure/200/e95e3d83e41f6c490efa2e8eba19aae8/CC1%2528C%2529OB%2528OC1%2528C%2529C%2529C1%253DCC%253DC2CN%2528%255BC%2540H%255D3CCC%2528%253DO%2529NC3%253DO%2529C%2528%253DO%2529C2%253DC1.png)

![Chemical structure of 3-[1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione - CSSB02495366511](/st/structure/200/011f93f67fe84e899982b65bc5ab8ac3/CC1%2528C%2529OB%2528OC1%2528C%2529C%2529C1%253DCC%253DC2C%2528CN%2528C3CCC%2528%253DO%2529NC3%253DO%2529C2%253DO%2529%253DC1.png)
![Chemical structure of (3S)-3-[1-oxo-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydro-1H-isoindol-2-yl]piperidine-2,6-dione - CSSB21511091594](/st/structure/200/be1eeefc477a73fe7c58cfec72325ac8/CC1%2528C%2529OB%2528OC1%2528C%2529C%2529C1%253DCC%253DC2C%2528CN%2528%255BC%2540H%255D3CCC%2528%253DO%2529NC3%253DO%2529C2%253DO%2529%253DC1.png)
![Chemical structure of N-[2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindol-5-yl]-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide - CSSB21531608971](/st/structure/200/8f32098d36f146900ac7fb64bdb366c0/CC1%2528C%2529OB%2528OC1%2528C%2529C%2529C1%253DCC%253DC%2528CC%2528%253DO%2529NC2%253DCC%253DC3CN%2528C4CCC%2528%253DO%2529NC4%253DO%2529C%2528%253DO%2529C3%253DC2%2529C%253DC1.png)
![Chemical structure of [2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindol-5-yl]boronic acid - CSSB06446546318](/st/structure/200/5d5da4c19f448f60e707b74b75bbe890/OB%2528O%2529c1ccc2CN%2528C3CCC%2528%253DO%2529NC3%253DO%2529C%2528%253DO%2529c2c1.png)
![Chemical structure of N-[2-(2,6-dioxopiperidin-3-yl)-3-oxo-2,3-dihydro-1H-isoindol-5-yl]-3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide - CSSB21531616176](/st/structure/200/201aa61b5569f57f86746863349e0ef4/CC1%2528C%2529OB%2528OC1%2528C%2529C%2529C1%253DCC%253DC%2528C%253DC1F%2529C%2528%253DO%2529NC1%253DCC%253DC2CN%2528C3CCC%2528%253DO%2529NC3%253DO%2529C%2528%253DO%2529C2%253DC1.png)
